Advanced search
Publication Cover
Breast Cancer: Targets and Therapy Volume 15, 2023 - Issue
Submit an article Journal homepage
396
Views
1
CrossRef citations to date
0
Altmetric
CASE REPORT

Recurrent Metaplastic Breast Cancer with Subtype Converted from Triple-Negative to HER2-Positive: A Case Report and Literature Review

Jing Wu1 Department of Breast Center, Chongqing Key Laboratory for Intelligent Oncology in Breast Cancer (iCQBC), Chongqing University Cancer Hospital, Chongqing, 400030, People’s Republic of ChinaView further author information
,
Yudi Jin2 Department of Pathology, Chongqing Key Laboratory for Intelligent Oncology in Breast Cancer (iCQBC), Chongqing University Cancer Hospital, Chongqing, 400030, People’s Republic of ChinaView further author information
,
Mei Liu1 Department of Breast Center, Chongqing Key Laboratory for Intelligent Oncology in Breast Cancer (iCQBC), Chongqing University Cancer Hospital, Chongqing, 400030, People’s Republic of ChinaView further author information
,
Ningsheng Zhu1 Department of Breast Center, Chongqing Key Laboratory for Intelligent Oncology in Breast Cancer (iCQBC), Chongqing University Cancer Hospital, Chongqing, 400030, People’s Republic of ChinaView further author information
,
Zhouhong Jing1 Department of Breast Center, Chongqing Key Laboratory for Intelligent Oncology in Breast Cancer (iCQBC), Chongqing University Cancer Hospital, Chongqing, 400030, People’s Republic of ChinaView further author information
&
Xiaohua Zeng1 Department of Breast Center, Chongqing Key Laboratory for Intelligent Oncology in Breast Cancer (iCQBC), Chongqing University Cancer Hospital, Chongqing, 400030, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 39-45 | Received 02 Nov 2022, Accepted 12 Jan 2023, Published online: 19 Jan 2023

References

  • Reddy TP, Rosato RR, Li X, et al. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Res. 2020;22(1):121. doi:10.1186/s13058-020-01353-z
  • El Zein D, Hughes M, Kumar S, et al. Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature. Clin Breast Cancer. 2017;17(5):382–391. doi:10.1016/j.clbc.2017.04.009
  • Wong W, Brogi E, Reis-Filho JS, et al. Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. NPJ Breast Cancer. 2021;7(1):96. doi:10.1038/s41523-021-00302-z
  • Leyrer CM, Berriochoa CA, Agrawal S, et al. Predictive factors on outcomes in metaplastic breast cancer. Breast Cancer Res Treat. 2017;165(3):499–504. doi:10.1007/s10549-017-4367-5
  • Toumi Z, Bullen C, Tang AC, et al. Metaplastic breast carcinoma: a case report and systematic review of the literature. Pathol Int. 2011;61(10):582–588. doi:10.1111/j.1440-1827.2011.02698.x
  • Haque W, Verma V, Naik N, et al. Metaplastic breast cancer: practice patterns, outcomes, and the role of radiotherapy. Ann Surg Oncol. 2018;25(4):928–936. doi:10.1245/s10434-017-6316-2
  • Tray N, Taff J, Adams S. Therapeutic landscape of metaplastic breast cancer. Cancer Treat Rev. 2019;79:101888. doi:10.1016/j.ctrv.2019.08.004
  • Xia LY, Xu WY, Hu QL. The different outcomes between breast-conserving surgery plus radiotherapy and mastectomy in metaplastic breast cancer: a population-based study. PLoS One. 2021;16(9):e0256893. doi:10.1371/journal.pone.0256893
  • Zhang J, Yang C, Lei C, et al. Survival outcomes after breast-conserving therapy compared with mastectomy for patients with early-stage metaplastic breast cancer: a population-based study of 2412 patients. Breast. 2021;58:10–17. doi:10.1016/j.breast.2021.03.010
  • Tadros AB, Sevilimedu V, Giri DD, et al. Survival outcomes for metaplastic breast cancer differ by histologic subtype. Ann Surg Oncol. 2021;28(8):4245–4253. doi:10.1245/s10434-020-09430-5
  • Li Y, Chen M, Pardini B, et al. The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database. J Transl Med. 2019;17(1):318. doi:10.1186/s12967-019-2069-y
  • Nowara E, Drosik A, Samborska-Plewicka M, et al. Metaplastic breast carcinomas - analysis of prognostic factors in a case series. Contemp Oncol. 2014;18(2):116–119. doi:10.5114/wo.2014.41392
  • Kalaw E, Lim M, Kutasovic JR, et al. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. Br J Cancer. 2020;123(11):1665–1672. doi:10.1038/s41416-020-01065-3
  • Jin C, Hacking S, Sajjan S, et al. GATA binding protein 3 (GATA3) as a marker for metaplastic spindle cell carcinoma of the breast. Pathol Res Pract. 2021;221:153413. doi:10.1016/j.prp.2021.153413
  • Shah VV, Duncan AD, Jiang S, et al. Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer. Nat Commun. 2021;12(1):5389. doi:10.1038/s41467-021-25650-z
  • Guo TH, Chen ZY, Xu JP, et al. Change of pathological type to metaplastic squamous cell carcinoma of the breast during disease recurrence: case report and literature review. Front Oncol. 2020;10:32. doi:10.3389/fonc.2020.00032
  • Chuthapisith S, Warnnissorn M, Amornpinyokiat N, et al. Metaplastic carcinoma of the breast with transformation from adenosquamous carcinoma to osteosarcomatoid and spindle cell morphology. Oncol Lett. 2013;6(3):728–732. doi:10.3892/ol.2013.1464
  • Miglietta F, Griguolo G, Bottosso M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer. 2021;7(1):137. doi:10.1038/s41523-021-00343-4
  • Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. doi:10.1056/NEJMoa2203690

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.